TOPICS

2018/06/07
Zebrafish-Based Drug Discovery and Systems Pharmacology

2017/12/01
フエノミクス個別化医療を実現

2017/11/25
Global Development in emerging zebrafish-based “alternative” methods

2017/11/25
ICH and 3Rs with zebrafish-based alternative methos

2017/11/23
171123日本動物実験代替法学会第 30 回大会シンポジウム6

》第127号 Flash News 「新たな白血病幹細胞治療薬の高速探索法開発に成功」

                     
2014/01/31

第127号 Flash Newsに1/21の記者会見の模様が掲載されました。

【Quantitative Phenotyping-Based In Vivo Chemical Screening in a Zebrafish Model of Leukemia Stem Cell Xenotransplantation 】

Beibei Zhang,Yasuhito Shimada,Junya Kuroyanagi,Noriko Umemoto,Yuhei Nishimura,Toshio Tanaka
Published: January 15, 2014・DOI:10.1371/journal.pone.0085439


Abstract

Zebrafish-based chemical screening has recently emerged as a rapid and efficient method to identify important compounds that modulate specific biological processes and to test the therapeutic efficacy in disease models, including cancer. In leukemia, the ablation of leukemia stem cells (LSCs) is necessary to permanently eradicate the leukemia cell population. However, because of the very small number of LSCs in leukemia cell populations, their use in xenotransplantation studies (in vivo) and the difficulties in functionally and pathophysiologically replicating clinical conditions in cell culture experiments (in vitro), the progress of drug discovery for LSC inhibitors has been painfully slow. In this study, we developed a novel phenotype-based in vivo screening method using LSCs xenotransplanted into zebrafish. Aldehyde dehydrogenase-positive (ALDH+) cells were purified from chronic myelogenous leukemia K562 cells tagged with a fluorescent protein (Kusabira-orange) and then implanted in young zebrafish at 48 hours post-fertilization. Twenty-four hours after transplantation, the animals were treated with one of eight different therapeutic agents (imatinib, dasatinib, parthenolide, TDZD-8, arsenic trioxide, niclosamide, salinomycin, and thioridazine). Cancer cell proliferation, and cell migration were determined by high-content imaging. Of the eight compounds that were tested, all except imatinib and dasatinib selectively inhibited ALDH+ cell proliferation in zebrafish. In addition, these anti-LSC agents suppressed tumor cell migration in LSC-xenotransplants. Our approach offers a simple, rapid, and reliable in vivo screening system that facilitates the phenotype-driven discovery of drugs effective in suppressing LSCs.

関連リンク

PLOS ONE 

関連ファイル

記者会見模様

新聞記事